Metabolic Profile as a Predictor of No-reflow in Diabetic Patients
1 other identifier
observational
120
0 countries
N/A
Brief Summary
to find metabolic factors that correlate with the development of no-reflow phenomenon that may help prevent its occurrence
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2021
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2021
CompletedFirst Submitted
Initial submission to the registry
April 2, 2021
CompletedFirst Posted
Study publicly available on registry
April 8, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2022
CompletedApril 8, 2021
April 1, 2021
1 year
April 2, 2021
April 7, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
detection correlation between DM and no-reflow phenomenon
measurment of random blood sugar in diabetic patients treated with primary Percutaneous Coronary Intervention ( PCI ) .and show its effects on reflow
baseline
Secondary Outcomes (2)
detection correlation between other metabolic factors as serum uric acid and no-reflow phenomenon
baseline
detection correlation between other metabolic factors as LDL\HDL and no-reflow phenomenon
baseline
Interventions
Blood samples were obtained before PCI, and the following parameters will be measured: 1- LDL-C (low-density lipoprotein cholesterol)\| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S
Eligibility Criteria
diabetic patients with STEMI treated with primary PCI
You may qualify if:
- diabetic patients with ST- elevation myocardial infarction (STEMI ) treated with primary Percutaneous Coronary Intervention ( PCI ) .
You may not qualify if:
- diabetic patients with ST- elevation myocardial infarction (STEMI ) treated with primary Percutaneous Coronary Intervention ( PCI ) : but have
- (1) a history of an unprotected left main artery with severe liver and kidney diseases or coronary artery bypass grafting .
- (2) patients who had valvular disease or cardiomyopathy . (3) severe dissection, thromboembolism in other parts, or vasospasm; and known malignancy .
- (4) patients with contraindications for anticoagulant therapy, such as active visceral hemorrhage, hemorrhagic stroke, or ischemic stroke within half a year (including transient ischemic attack), or aortic dissection, or patients with hematological diseases complicated with coagulation disorders .
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- El Zahraa Gamallead
Related Publications (1)
Bernstein JM, Lee J, Conboy K, Ellis E, Li P. The role of IgE mediated hypersensitivity in recurrent otitis media with effusion. Am J Otol. 1983 Jul;5(1):66-9. No abstract available.
PMID: 6683937BACKGROUND
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Metabolic profile as a predictor of no reflow in diabetic patients treated with primary Percutaneous Coronary Intervention (PCI) .
Study Record Dates
First Submitted
April 2, 2021
First Posted
April 8, 2021
Study Start
April 1, 2021
Primary Completion
April 1, 2022
Study Completion
April 1, 2022
Last Updated
April 8, 2021
Record last verified: 2021-04